

Page 31, line 26: after "YSFKPMPLaR" insert --(SEQ ID NO:1)---.

Page 31, line 27: after "YKQGGFLGLYSFKPMPLaR" insert --(SEQ ID NO:2)---.

Page 31, line 31: after "YSFKPMPLaRKQGGFLGL" insert --(SEQ ID NO:5)---.

Page 36, line 36: after "K-Ahx-YSFKPMPLaR" insert --(SEQ ID NO:8)---.

Page 37, line 12: before "and" insert --(SEQ ID NO:8)---.

Page 38, line 36: before "covalently" insert --(SEQ ID NO:9)---.

Page 39, line 1: after "(YSFKPMPLaR)" insert --(SEQ ID NO:1)---.

Page 39, line 7: before "construct" insert --(SEQ ID NO:10)---.

Page 47, line 29: before "and" insert --(SEQ ID NO:2)---.

Page 47, line 32: after "KLH" insert --(SEQ ID NO:6)---.

Page 48, line 1: before "and" insert --(SEQ ID NO:9)---.

Page 48, line 2: after "GDLSDPGNRTNLGGRDSL" insert --(SEQ ID NO:11)---.

After the last page of the specification, and before the first page of claims, please insert the paper copy of the Sequence Listing submitted herewith.

In the claims:

18. (Amended) A method for enhancing an [activating an antigen presenting cell for inducing an enhanced] immune response to an immunogen by activating an antigen presenting cell, [said immunogen being delivered to the antigen presenting pathway of said antigen presenting cell,] said method comprising binding to a characteristic surface determinant of said antigen presenting cell a molecular adjuvant [as claimed in claim 1] comprising a targeting ligand having binding affinity for said characteristic determinant, said targeting ligand being functionally linked to

said immunogen, said binding activating said antigen presenting cell and effecting delivery of said immunogen to an antigen presenting pathway of said antigen presenting cell, thereby enhancing said immune response.

22. (Amended) The method of claim 18, adapted [A method] for eliciting an antigen presenting cell-mediated immune response in a host susceptible to infection by an antigen containing disease causing agent, said method comprising administering to said individual said [a] molecular adjuvant, [as claimed in claim 1], wherein said immunogen comprises the antigen of said disease causing agent, in an amount effective for eliciting said immune response.

23. (Amended) The method of claim 18, adapted [A method] for eliciting an immune response to a tumor-associated antigen, said method comprising administering to a host having a tumor expressing said tumor-associated antigen said [a] molecular adjuvant [as claimed in claim 1], wherein said immunogen comprises said tumor-associated antigen, in an amount effective for eliciting said immune response.

Claim 24, line 3: change "immunogenic" to  
--immunogenically--;

Claim 24, line 5: change "form" to --from--.

Please add the following new claim:

25. Antibodies produced by the method of claim 24.

REMARKS

The specification has been amended to provide the patent number of now-issued U.S. Application No. 08/299,285, and to enter a Sequence Listing and provide Sequence I.D. Numbers in